IPO Summary: Aktis Oncology, Inc. (AKTS) Delivers Breakout to Open 2026 Calendar
Aktis Oncology (AKTS US) delivered a strong debut to kick off the 2026 IPO market, marking a clear win for both new issuance and the biotech sector. The deal was upsized to 17.65 million shares ahead of pricing, ultimately pricing at the top of the range at $18.00. Shares opened at $27.00, representing an immediate 50%[…]
